Shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) have been assigned an average recommendation of “Hold” from the twelve research firms that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $7.03.
Several research analysts recently commented on the stock. Zacks Investment Research downgraded shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 10th. ValuEngine downgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 10th. BidaskClub downgraded shares of Adaptimmune Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, March 26th. Roth Capital initiated coverage on shares of Adaptimmune Therapeutics in a report on Friday. They set a “buy” rating and a $7.00 price objective on the stock. Finally, Svb Leerink restated a “market perform” rating and set a $5.00 price objective (down previously from $12.00) on shares of Adaptimmune Therapeutics in a report on Tuesday, May 7th.
ADAP traded up $0.05 during trading on Thursday, hitting $3.54. The stock had a trading volume of 1,100 shares, compared to its average volume of 398,201. The company has a market capitalization of $369.56 million, a PE ratio of -3.68 and a beta of 1.56. Adaptimmune Therapeutics has a 12 month low of $3.20 and a 12 month high of $14.54. The company has a debt-to-equity ratio of 0.12, a current ratio of 8.55 and a quick ratio of 8.55.
Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its earnings results on Monday, May 6th. The biotechnology company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative net margin of 161.09% and a negative return on equity of 45.03%. Analysts anticipate that Adaptimmune Therapeutics will post -1.2 earnings per share for the current year.
Several large investors have recently bought and sold shares of the company. Morgan Stanley increased its holdings in shares of Adaptimmune Therapeutics by 381.4% during the 1st quarter. Morgan Stanley now owns 236,787 shares of the biotechnology company’s stock worth $1,018,000 after purchasing an additional 187,604 shares during the period. Man Group plc increased its stake in Adaptimmune Therapeutics by 28.2% in the first quarter. Man Group plc now owns 1,338,630 shares of the biotechnology company’s stock valued at $5,756,000 after acquiring an additional 294,619 shares during the period. Oxford Asset Management LLP increased its stake in Adaptimmune Therapeutics by 14.0% in the first quarter. Oxford Asset Management LLP now owns 53,449 shares of the biotechnology company’s stock valued at $230,000 after acquiring an additional 6,557 shares during the period. Renaissance Technologies LLC increased its stake in Adaptimmune Therapeutics by 26.9% in the first quarter. Renaissance Technologies LLC now owns 794,500 shares of the biotechnology company’s stock valued at $3,416,000 after acquiring an additional 168,200 shares during the period. Finally, Rathbone Brothers plc increased its stake in Adaptimmune Therapeutics by 27.9% in the first quarter. Rathbone Brothers plc now owns 285,722 shares of the biotechnology company’s stock valued at $1,229,000 after acquiring an additional 62,292 shares during the period. Institutional investors own 66.30% of the company’s stock.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
Recommended Story: Asset Allocation
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.